enGene injects new hope into the future of bladder cancer care
Ron Cooper, ex-Albireo CEO, is betting on enGene’s novel gene delivery platform to sidestep BCG shortfalls and transform bladder cancer treatment worldwide.
Ron Cooper, ex-Albireo CEO, is betting on enGene’s novel gene delivery platform to sidestep BCG shortfalls and transform bladder cancer treatment worldwide.